Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
第2相
早期終了
NCT05581589
| 対象疾患 | Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 |
|---|
| 相 | 第2相 |
|---|
| スポンサー | University of Washington |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 4 名 |
|---|
| 介入（薬剤） | Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan |
|---|
| 開始日 | 2023年6月15日 |
|---|
| 完了日 | 2024年10月15日 |
|---|
| 結果公開日 | 2026年4月27日 |
|---|
概要
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan before radical cystectomy may make the surgery more effective in patients with muscle invasive bladder cancer.
Pathologic Complete Response (pCR Defined as ypT0N0)
At radical cystectomy (Radical cystectomy is expected to occur within 2-6 weeks after the last neoadjuvant trial therapy dose) · Participants
| Treatment (Sacituzumab Govitecan) | 1 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。